Apexigen: Developing CD40 agonist mAb; 170+ pts dosed in single agent and combi settings. 7 ongoing Ph 2s, undisclosed ocular disease program in Ph 3. Data from Ph 1b of Ph 1/2 1L panc cancer trial (collab w/Parker: combi w/nivo & SOC) to be presented at AACR Mar 2019. $93M funding to date (Decheng, 3E, Virtus, SV Tech, Ally Bridge). Collabs w/BMY, MDACC, Yale, Parker, Neon, UCSF, Columbia, et al. Data from 9 ongoing mono & combi trials (panc, esophageal, melanoma, sarcoma, NSCLC, ped brain, renal; PD1 resistant and refractory; combi w vaccines) anticipated '19 & '20.
Biotech Company
Disease Space
75 Shoreway Road
Suite C
San Carlos, CA 94070
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019